Relmada Therapeutics (RLMD) Other Non-Current Liabilities (2014 - 2026)
Relmada Therapeutics (RLMD) reported Other Non-Current Liabilities of $3.7 million for Q1 2026, up 365.81% year-over-year from $802590.0 in Q1 2025, and up 252.39% quarter-over-quarter from $1.1 million in Q4 2025.
Relmada Therapeutics (RLMD) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 8 years of Other Non-Current Liabilities data on file, last reported at $3.7 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $3.7 million, up 365.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 365.81% YoY), and the FY2025 annual result was $1.1 million, up 23650.41% from the prior year.
- Other Non-Current Liabilities climbed to $3.7 million in Q1 2026 per RLMD's latest filing, from $1.1 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $3.7 million in Q1 2026 and troughed at $4467.0 in Q4 2024.
- A 3-year average of $838908.0 and a median of $221107.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities surged 23650.41% in 2025, then soared 365.81% in 2026.
- A 3-year view of Other Non-Current Liabilities shows it stood at $4467.0 in 2024, then surged by 23650.41% to $1.1 million in 2025, then soared by 252.39% to $3.7 million in 2026.
- Business Quant data shows RLMD's Other Non-Current Liabilities at $3.7 million in Q1 2026, $1.1 million in Q4 2025, and $221107.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.74 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 221,107.00 |
| Jun 30, 2025 | 32,116.00 |
| Mar 31, 2025 | 802,590.00 |
| Dec 31, 2024 | 4,467.00 |
| Sep 30, 2024 | 12,562.00 |
| Jun 30, 2018 | 4.19 Mn |
| Jun 30, 2017 | 175,853.00 |
| Mar 31, 2017 | 139,421.00 |
| Dec 31, 2016 | 137,078.00 |
| Sep 30, 2016 | 134,736.00 |
| Jun 30, 2016 | 892,503.00 |
| Mar 31, 2016 | 108,985.00 |
| Jun 30, 2015 | 14.00 Mn |
| Mar 31, 2015 | 100,000.00 |
| Dec 31, 2014 | 100,000.00 |
| Jun 30, 2014 | 25.59 Mn |